Wangyi

1、Educational Experience

(1) 2017/09-2022/06, China pharmaceutical university, College of Pharmacy, PhD

(2) 2013/09-2017/06, China pharmaceutical university, College of Pharmacy, Bachelor

2、Working Experience

(1) 2022/06-now, China pharmaceutical university, College of Pharmacy, Post-doctor

1. Qi, L.Y.; Wang, Y.; Hu, L.F.; Zhao, P.S.; Yu, H.Y.; Xing, L.; Gao, X.D.*; Cao, Q.R.*; Jiang, H.L.* Enhanced nuclear gene delivery via integrating and streamlining intracellular pathway. J Control Release. 2022;341:511-523. (IF: 11.467).

2. Wang, Y.; Hu, L.F.; Cui, P.F.; Qi, L.Y.; Xing. L.*; Jiang, H.L.* Pathologically responsive mitochondrial gene therapy in an allotopic expression-independent manner cures Leber’s hereditary optic neuropathy. Adv Mater. 2021;33:2103307. (IF: 30.849).

3. Wang, Y.; Hu, L.F.; Zhou, T.J.; Qi, L.Y.; Xing, L.; Lee, J.; Wang, F.Z.; Oh, Y.K.*; Jiang, H.L.* Gene therapy strategies for rare monogenic disorders with nuclear or mitochondrial gene mutations. Biomaterials. 2021;277:121108. (IF: 12.479).

4. Chang, X.; Xing, L.; Wang, Y.; Yang, C.X.; He, Y.J.; Zhou, T.J.; Gao, X.D.; Li. L.; Hao. H.P.*; Jiang, H.L.* Monocyte-derived multipotent cell delivered programmed therapeutics to reverse idiopathic pulmonary fibrosis. Sci Adv. 2020;6:eaba3167, (IF: 13.116).

5. Xing, L.; Gong, J.H.; Wang, Y.; Zhu, Y.; Huang, Z.J.; Zhao, J.; Li, F.; Wang, J.H.*; Wen, H.*; Jiang, H.L.* Hypoxia alleviation-triggered enhanced photodynamic therapy in combination with IDO inhibitor for preferable cancer therapy. Biomaterials. 2019;206:170-182. (IF: 10.273).

(1) The fellowship of China Postdoctoral Science Foundation, 2022M720173, 2023.01-2025.12.

(1) In situ mitochondrial gene therapy: Leber hereditary optic neuropathy (LHON) is a rare genetic disease that causes inherited blindness due to mutations in mitochondrial DNA (mtDNA). There are no effective treatments for LHON, and the existing chemotherapeutic agent Idebenone has limited efficacy. Therefore, we developed an in situ mitochondrial gene therapy to correct mtDNA mutations by delivering functional genes directly into the mitochondrial matrix, which provides a promising method for the treatment of refractory LHON and other mtDNA mutation diseases.